Glutathione and N-acetylcysteine conjugates of alpha-methyldopamine produce serotonergic neurotoxicity: possible role in methylenedioxyamphetamine-mediated neurotoxicity.

Direct injection of either 3,4-(+/-)-methylenedioxymethamphetamine (MDMA) or 3,4-(+/-)-methylenedioxyamphetamine (MDA) into the brain fails to reproduce the serotonergic neurotoxicity seen following peripheral administration. The serotonergic neurotoxicity of MDA and MDMA therefore appears to be dependent upon the generation of a neurotoxic metabolite, or metabolites, the identity of which remains unclear. alpha-Methyldopamine (alpha-MeDA) is a major metabolite of both MDA and MDMA. We have shown that intracerebroventricular (icv) injection of 2,5-bis(glutathion-S-yl)-alpha-methyldopamine [2, 5-bis(glutathion-S-yl)-alpha-MeDA] causes decreases in serotonin concentrations in the striatum, cortex, and hippocampus, and neurobehavioral effects similar to those seen following MDA and MDMA administration. In contrast, although 5-(glutathion-S-yl)-alpha-methyldopamine [5-(glutathion-S-yl)-alpha-MeDA] and 5-(N-acetylcystein-S-yl)-alpha-methyldopamine [5-(N-acetylcystein-S-yl)-alpha-MeDA] produce neurobehavioral changes similar to those seen with MDA and MDMA, and acute changes in brain 5-HT and dopamine concentrations, neither conjugate caused long-term decreases in 5-HT concentrations. We now report that direct intrastriatal or intracortical administration of 5-(glutathion-S-yl)-alpha-MeDA (4 x 200 or 4 x 400 nmol), 5-(N-acetylcystein-S-yl)-alpha-MeDA (4 x 7 or 4 x 20 nmol), and 2, 5-bis(glutathion-S-yl)-alpha-MeDA (4 x 150 or 4 x 300 nmol) causes significant decreases in striatal and cortical 5-HT concentrations (7 days following the last injection). Interestingly, intrastriatal injection of 5-(glutathion-S-yl)-alpha-MeDA or 2, 5-bis(glutathion-S-yl)-alpha-MeDA, but not 5-(N-acetylcystein-S-yl)-alpha-methyldopamine, also caused decreases in 5-HT concentrations in the ipsilateral cortex. The same pattern of changes was seen when the conjugates were injected into the cortex. The effects of the thioether conjugates of alpha-MeDA were confined to 5-HT nerve terminal fields, since no significant changes in monoamine neurotransmitter levels were detected in brain regions enriched with 5-HT cell bodies (midbrain/diencephalon/telencephalon and pons/medulla). In addition, the effects of the conjugates were selective with respect to the serotonergic system, as no significant changes were seen in dopamine or norepinephrine concentrations. The results indicate that thioether conjugates of alpha-MeDA are selective serotonergic neurotoxicants. Nonetheless, a role for these conjugates in the toxicity observed following systemic administration of MDA and MDMA remains to be demonstrated, and requires further experimentation.

[1]  E. Lock,et al.  Symposium overview: the role of glutathione in neuroprotection and neurotoxicity. , 1999, Toxicological sciences : an official journal of the Society of Toxicology.

[2]  H. Li,et al.  Brain Mitochondria Catalyze the Oxidation of 7‐(2‐Aminoethyl)‐3,4‐Dihydro‐5‐Hydroxy‐2H‐1,4‐Benzothiazine‐3‐Carboxylic Acid (DHBT‐1) to Intermediates that Irreversibly Inhibit Complex I and Scavenge Glutathione: Potential Relevance to the Pathogenesis of Parkinson's Disease , 1998, Journal of neurochemistry.

[3]  K. Kovar,et al.  Chemistry and Pharmacology of Hallucinogens, Entactogens and Stimulants , 1998, Pharmacopsychiatry.

[4]  T. Monks,et al.  Biological reactivity of polyphenolic-glutathione conjugates. , 1997, Chemical research in toxicology.

[5]  T. Montine,et al.  Neurotoxicity of Endogenous Cysteinylcatechols , 1997, Experimental Neurology.

[6]  G. Dryhurst,et al.  Irreversible Inhibition of Mitochondrial Complex I by 7‐(2‐Aminoethyl)‐3,4‐Dihydro‐5‐Hydroxy‐2H‐1,4‐Benzothiazine‐3‐Carboxylic Acid (DHBT‐1): A Putative Nigral Endotoxin of Relevance to Parkinson's Disease , 1997, Journal of neurochemistry.

[7]  B. Mannervik,et al.  Glutathione transferases catalyse the detoxication of oxidized metabolites (o-quinones) of catecholamines and may serve as an antioxidant system preventing degenerative cellular processes. , 1997, The Biochemical journal.

[8]  R. T. Miller,et al.  2,5-Bis-(glutathion-S-yl)-alpha-methyldopamine, a putative metabolite of (+/-)-3,4-methylenedioxyamphetamine, decreases brain serotonin concentrations. , 1997, European journal of pharmacology.

[9]  C. Welch,et al.  Human Class Mu Glutathione Transferases, in Particular Isoenzyme M2-2, Catalyze Detoxication of the Dopamine Metabolite Aminochrome* , 1997, The Journal of Biological Chemistry.

[10]  G. Dryhurst,et al.  Oxidation of dopamine in the presence of cysteine: characterization of new toxic products. , 1997, Chemical research in toxicology.

[11]  B. Xia,et al.  Synthesis, redox properties, in vivo formation, and neurobehavioral effects of N-acetylcysteinyl conjugates of dopamine: possible metabolites of relevance to Parkinson's disease. , 1996, Chemical research in toxicology.

[12]  G. Dryhurst,et al.  Further insights into the influence of L-cysteine on the oxidation chemistry of dopamine: reaction pathways of potential relevance to Parkinson's disease. , 1996, Chemical research in toxicology.

[13]  R. T. Miller,et al.  Effects of intracerebroventricular administration of 5-(glutathion-S-yl)-alpha-methyldopamine on brain dopamine, serotonin, and norepinephrine concentrations in male Sprague-Dawley rats. , 1996, Chemical research in toxicology.

[14]  J. Richards,et al.  Methylenedioxymethamphetamine-induced serotonin deficits are followed by partial recovery over a 52-week period. Part II: Radioligand binding and autoradiography studies. , 1996, The Journal of pharmacology and experimental therapeutics.

[15]  C. Epstein,et al.  Superoxide radicals mediate the biochemical effects of methylenedioxymethamphetamine (MDMA): Evidence from using CuZn‐superoxide dismutase transgenic mice , 1995, Synapse.

[16]  R. T. Miller,et al.  Metabolism of 5-(glutathion-S-yl)-alpha-methyldopamine following intracerebroventricular administration to male Sprague-Dawley rats. , 1995, Chemical research in toxicology.

[17]  D. Nichols,et al.  The monoamine oxidase-B inhibitor L-deprenyl protects against 3,4-methylenedioxymethamphetamine-induced lipid peroxidation and long-term serotonergic deficits. , 1995, The Journal of pharmacology and experimental therapeutics.

[18]  P. Dyment,et al.  Increasing use of "Ecstasy" (MDMA) and other hallucinogens on a college campus. , 1994, Journal of American college health : J of ACH.

[19]  S. Dawling,et al.  Toxicity and deaths from 3,4-methylenedioxymethamphetamine ("ecstasy") , 1992, The Lancet.

[20]  K. Cunningham,et al.  Lack of serotonin neurotoxicity after intraraphe microinjection of (+)-3,4-methylenedioxymethamphetamine (MDMA) , 1992, Brain Research Bulletin.

[21]  M. Molliver,et al.  Dual serotoninergic projections to forebrain in the rat: Morphologically distinct 5‐HT axon terminals exhibit differential vulnerability to neurotoxic amphetamine derivatives , 1991, The Journal of comparative neurology.

[22]  A. Cho,et al.  Transformation of dopamine and alpha-methyldopamine by NG108-15 cells: formation of thiol adducts. , 1991, Chemical research in toxicology.

[23]  U. McCann,et al.  Major metabolites of(±)3,4-methylenedioxyamphetamine (MDA) do not mediate its toxic effects on brain serotonin neurons , 1991, Brain Research.

[24]  C. J. Schmidt,et al.  Methylenedioxymethamphetamine-induced hyperthermia and neurotoxicity are independently mediated by 5-HT2 receptors , 1990, Brain Research.

[25]  I. Törk.  Anatomy of the Serotonergic System a , 1990, Annals of the New York Academy of Sciences.

[26]  A. Cho,et al.  Metabolism of methylenedioxymethamphetamine: formation of dihydroxymethamphetamine and a quinone identified as its glutathione adduct. , 1990, The Journal of pharmacology and experimental therapeutics.

[27]  C. J. Schmidt,et al.  Antagonism of the neurotoxicity due to a single administration of methylenedioxymethamphetamine. , 1990, European journal of pharmacology.

[28]  T. Monks,et al.  Glutathione, gamma-glutamyl transpeptidase, and the mercapturic acid pathway as modulators of 2-bromohydroquinone oxidation. , 1990, Toxicology and applied pharmacology.

[29]  G. Hanson,et al.  Acute inactivation of tryptophan hydroxylase by amphetamine analogs involves the oxidation of sulfhydryl sites. , 1989, European journal of pharmacology.

[30]  R. Foltz,et al.  In vivo and in vitro metabolism of 3,4-(methylenedioxy)methamphetamine in the rat: identification of metabolites using an ion trap detector. , 1988, Chemical research in toxicology.

[31]  C. J. Schmidt,et al.  Direct central effects of acute methylenedioxymethamphetamine on serotonergic neurons. , 1988, European journal of pharmacology.

[32]  G. Hanson,et al.  Role of endogenous dopamine in the central serotonergic deficits induced by 3,4-methylenedioxymethamphetamine. , 1988, The Journal of pharmacology and experimental therapeutics.

[33]  G. Battaglia,et al.  Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity , 1988, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[34]  J. Langston,et al.  Toxic effects of MDMA on central serotonergic neurons in the primate: importance of route and frequency of drug administration , 1988, Brain Research.

[35]  I. Törk,et al.  Serotoninergic innervation of the cat cerebral cortex , 1988, The Journal of comparative neurology.

[36]  M. Molliver.  Serotonergic Neuronal Systems: What Their Anatomic Organization Tells Us about Function , 1987, Journal of clinical psychopharmacology.

[37]  G. Hanson,et al.  Immediate and long-term effects of 3,4-methylenedioxymethamphetamine on serotonin pathways in brain of rat , 1987, Neuropharmacology.

[38]  E. D. De Souza,et al.  3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites. , 1987, The Journal of pharmacology and experimental therapeutics.

[39]  L S Seiden,et al.  Biochemical and histological evidence that methylenedioxymethylamphetamine (MDMA) is toxic to neurons in the rat brain. , 1987, The Journal of pharmacology and experimental therapeutics.

[40]  G. Hanson,et al.  The effects of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) on monoaminergic systems in the rat brain. , 1986, European journal of pharmacology.

[41]  L. Seiden,et al.  Hallucinogenic amphetamine selectively destroys brain serotonin nerve terminals. , 1985, Science.

[42]  K. Midha,et al.  alpha-Methyldopamine, a key intermediate in the metabolic disposition of 3,4-methylenedioxyamphetamine in vivo in dog and monkey. , 1978, Drug metabolism and disposition: the biological fate of chemicals.

[43]  G. Ricaurte,et al.  Synthesis and neurotoxicological evaluation of putative metabolites of the serotonergic neurotoxin 2-(methylamino)-1-[3,4-(methylenedioxy)phenyl] propane [(methylenedioxy)methamphetamine]. , 1992, Chemical research in toxicology.

[44]  C. J. Schmidt,et al.  5-HT2 antagonists stereoselectively prevent the neurotoxicity of 3,4-methylenedioxymethamphetamine by blocking the acute stimulation of dopamine synthesis: reversal by L-dopa. , 1991, The Journal of pharmacology and experimental therapeutics.

[45]  W. Slikker,et al.  Influence of inducers and inhibitors on the metabolism in vitro and neurochemical effects in vivo of MDMA. , 1989, Neurotoxicology.

[46]  B. Kosofsky,et al.  The serotoninergic innervation of cerebral cortex: Different classes of axon terminals arise from dorsal and median raphe nuclei , 1987, Synapse.

[47]  D. Cook,et al.  The properties of 3,4-methylenedioxyamphetamine (MDA). I. A review of the literature. , 1973, Clinical toxicology.